Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery

Clin Lung Cancer. 2021 Jul;22(4):e528-e532. doi: 10.1016/j.cllc.2020.04.012. Epub 2020 Jun 4.
No abstract available

Keywords: ALK; Alectinib hepatotoxicity; CNS efficacy of brigatinib; CNS relapse; Dose-escalated brigatinib.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anaplastic Lymphoma Kinase / genetics
  • Brain Neoplasms / pathology
  • Brain Neoplasms / secondary
  • Brain Neoplasms / therapy*
  • Carbazoles / administration & dosage
  • Carbazoles / adverse effects
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Chemical and Drug Induced Liver Injury / etiology
  • Combined Modality Therapy
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Neoplasm Recurrence, Local
  • Organophosphorus Compounds / administration & dosage
  • Piperidines / administration & dosage
  • Piperidines / adverse effects
  • Protein Kinase Inhibitors / administration & dosage*
  • Protein Kinase Inhibitors / adverse effects
  • Pyrimidines / administration & dosage
  • Radiosurgery
  • Treatment Outcome

Substances

  • Carbazoles
  • Organophosphorus Compounds
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • brigatinib
  • alectinib